This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Exelixis (EXEL) Gains 14.9% in a Week on Strong Q2 Results
by Zacks Equity Research
Exelixis' (EXEL) shares rally following an impressive performance in the second quarter, buoyed by a surge in license revenues.
Entrada Therapeutics, Inc. (TRDA) Tops Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Entrada Therapeutics (TRDA) delivered earnings and revenue surprises of 138.46% and 72.17%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Esperion's (ESPR) Q2 Loss Narrows, Revenues Soar Year Over Year
by Zacks Equity Research
Esperion (ESPR) reports a narrower-than-expected loss for the second quarter of 2024. Revenues beat estimates. Sales rise year over year owing to higher collaboration revenues.
Merck (MRK) to Buy Curon's Bispecific Antibody Drug for $1.3B
by Zacks Equity Research
Merck (MRK) to acquire worldwide rights to a novel investigational clinical-stage bispecific antibody for treating B-cell-associated diseases. The deal is expected to close by third-quarter 2024.
Pacira (PCRX) Plummets as US Court Deems Exparel Patent Invalid
by Zacks Equity Research
Pacira (PCRX) falls 48% as the District Court of New Jersey rules that the company's '495 patent for its lead drug, Exparel, is not valid.
Avidity Biosciences, Inc. (RNA) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Avidity Biosciences (RNA) delivered earnings and revenue surprises of 14.47% and 71.16%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Insmed (INSM) Lags on Q2 Earnings, Tops Sales, Reiterates View
by Zacks Equity Research
Insmed (INSM) posts mixed second-quarter results. It reaches alignment with the FDA on the primary endpoint of a late-stage study that seeks to expand the label of Arikayce.
Intellia's (NTLA) Q2 Earnings & Revenues Fall Shy of Estimates
by Zacks Equity Research
Intellia's (NTLA) second-quarter 2024 earnings and revenues lag estimates. The company provides developmental and regulatory updates on its pipeline candidates.
Novavax (NVAX) Lags on Q2 Earnings & Sales, Cuts '24 Outlook
by Zacks Equity Research
Novavax (NVAX) posts dismal second-quarter results. It also slashes its total revenue guidance, citing lower COVID-19 vaccine uptake.
Nektar's (NKTR) Q2 Earnings Lag Estimates, Revenues Top
by Zacks Equity Research
Nektar (NKTR) reports a wider-than-expected loss in the second quarter of 2024 while revenues beat estimates. Stock falls in after-hours trading.
Cytokinetics (CYTK) Q2 Loss Wider Than Expected, Pipeline in Focus
by Zacks Equity Research
Cytokinetics (CYTK) reports wider-than-expected Q2 loss as operating expenses increase. CYTK is on track to complete the rolling NDA submission for aficamten in the third quarter.
Gilead (GILD) Q2 Earnings Beat, Annual Profit Guidance Raised
by Zacks Equity Research
Gilead (GILD) Q2 earnings and sales beat estimates on high HIV, oncology and liver disease drug sales and low expenses.
Iovance (IOVA) Q2 Earnings Beat, Stock Up on Upbeat Sales View
by Zacks Equity Research
Iovance (IOVA) reports better-than-expected second-quarter results. Shares price rises on the back of encouraging product revenue guidance issued by management for 2024 and 2025.
Mirum's (MIRM) Q2 Earnings Lag Estimates, Revenues Top
by Zacks Equity Research
Mirum's (MIRM) earnings miss estimates in the second quarter of 2024 while revenues beat the same. Livmarli drives year-over-year sales.
SpringWorks (SWTX) Q2 Earnings Beat, Ogsiveo Drives Revenues
by Zacks Equity Research
SpringWorks (SWTX) reports better-than-expected second-quarter results. The newly approved desmoid tumor drug, Ogsiveo, witnesses a strong launch.
Kymera (KYMR) Q2 Loss Narrower Than Expected, Pipeline in Focus
by Zacks Equity Research
Kymera (KYMR) reports a narrower-than-expected loss in the second quarter. The company expects the current cash balance to provide a runway into the first half of 2027.
Viatris (VTRS) Q2 Earnings Outpace Estimates, Sales Miss
by Zacks Equity Research
Viatris' (VTRS) earnings beat estimates in the second quarter but sales miss the same. New products are performing well and the rise in annual guidance for these products' sales is encouraging.
Allogene (ALLO) Posts Narrower Than Expected Loss in Q2
by Zacks Equity Research
Allogene's (ALLO) second-quarter earnings beat estimates but sales miss the mark. It expects to submit a regulatory filing with the FDA for its lead pipeline drug in large B-cell lymphoma indication by 2027.
Monte Rosa Therapeutics (GLUE) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Monte Rosa Therapeutics (GLUE) delivered earnings and revenue surprises of 14% and 46.58%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Sarepta (SRPT) Q2 Earnings Top Estimates, Sales Lag, View Weak
by Zacks Equity Research
Sarepta (SRPT) reports mixed results in the second quarter. It issues revenue guidance for 2025, which is below expectations. Stock falls during after-market trading.
Exelixis (EXEL) Q2 Earnings Beat, Milestone Payments Fuel Revenues
by Zacks Equity Research
Exelixis (EXEL) beats on earnings and sales in the second quarter. Its shares are trading up in response to the results.
Madrigal (MDGL) Tops on Q2 Earnings, NASH Drug Drives Top Line
by Zacks Equity Research
Madrigal (MDGL) posts better than expected second-quarter numbers. It adds nearly $15 million from sales of the first-ever NASH drug Rezdiffra, which is encouraging for a drug launched in April 2024.
Beam Therapeutics (BEAM) Q2 Earnings Beat, Revenues Miss
by Zacks Equity Research
Beam Therapeutics (BEAM) reports mixed second-quarter results. The company remains focused on pipeline development.
Caribou Biosciences, Inc. (CRBU) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Caribou Biosciences (CRBU) delivered earnings and revenue surprises of 6.67% and 4.56%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
BioMarin (BMRN) Q2 Earnings & Sales Top Estimates, Ups '24 View
by Zacks Equity Research
BioMarin (BMRN) posts better-than-expected second quarter earnings. It also raises its revenue and earnings guidance for full-year 2024.